Symmetry Medical Inc. (SMA) Q2 2010 Earnings Conference Call August 5, 2010 8:00 AM ET Executives Carol Ruth – IR, The Ruth Group Brian Moore – President and CEO Fred Hite – SVP and CFO Analysts Matt Miksic – Piper Jaffray James Sidoti – Sidoti & Co. Michael Matson – Wells Fargo Securities PresentationOperator
Good day ladies and gentlemen and welcome to the second quarter 2010 Symmetry Medical Inc earnings conference call. My name is Josh and I will be your coordinator for today. At this time all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of this conference. (Operator Instructions) At this time, I will turn the call over to Carol Ruth from the Ruth Group. Carol, you may proceed. Carol Ruth Welcome to the Symmetry Medical second quarter conference call. Joining us on the call are Brian Moore, the President and Chief Executive Officer and Fred Hite, Senior Vice President and Chief Financial Officer. Statements in this conference call regarding Symmetry Medical business which are not historical facts may be forward-looking statements that involve risks and uncertainties within the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as may, will, should, expect, believe, anticipate, plan, estimate, intend and similar words indicating possible future expectations, events or actions. Such predicative statements are not guarantees of future performance and actual results and outcome could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to, the loss of one or more customers, the development of new products or product innovation by our competitors, product liability, changes in management, changes in conditions affecting the economy, orthopedic device manufacturers, or the medical device industry in general and changes in government regulation of medical devices and third party reimbursement practices.